Results 91 to 100 of about 13,977 (118)
Supplementary figure S1. Differential sensitivity of human AML LSCs to JQ1. Supplementary figure S2. Relative levels of the autophagy pathway effectors LC3-II, beclin-1, and pULK1 (S555). Supplementary figure S3. Autophagy induction in KG1 and KG1a cells
Ji Eun Jang (8135850) +6 more
core +1 more source
Natural history specimen data linked to collectors and determiners held within, "Systematics of the Ameerega rubriventris complex (Anura: Dendrobatidae) with descriptions of two new cryptic species from the East-Andean versant of Peru".
Bionomia
core +1 more source
The MYC-independent effects of BET inhibitor JQ1 on super-enhancers in cancer
MYC overexpression plays an important role in cancer progression and is a common feature of many cancer types. One reason is due to the invasion of super-enhancer regions by MYC upstream of oncogenes, often resulting in activation of oncogenic pathways ...
Chia, Boon Jun
core
Unlocking the "undruggable": current landscape and emerging frontiers in lysosomal receptor-mediated protein degradation. [PDF]
Ma YM, Xia HF, Xiao YL, Yu ZL.
europepmc +1 more source
Background/Purpose: Systemic sclerosis (SSc) is a complex pro-inflammatory scarring disease, characterised by elevated deposition of extracellular matrix (ECM) proteins, in particular collagen type I.
Holmes, A +6 more
core
The Senolytic Drug JQ1 Removes Senescent Cells via Ferroptosis
BACKGROUND: Ferroptosis is an iron-dependent, non-apoptotic programmed cell death. Cellular senescence contributes to aging and various age-related diseases through the expression of a senescence-associated secretory phenotype (SASP). Senescent cells are
Kim Byung-Soo +2 more
exaly +2 more sources
Bromodomain and extraterminal domain protein inhibitors (BETi) for cancer treatment did not convince during their first clinical trials. Their epigenetic mechanism of action is still not well understood, even if MYC is generally considered as its main ...
Simo Schwartz +2 more
exaly +2 more sources

